Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics. - Wikidata - wikimedia - TriplyDB

Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.

Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.

http://www.wikidata.org/entity/Q37866298

about

HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" study Short communication: Tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected women.Highlights from the 2012 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the search of an HIV cure.Evaluating the association of single-nucleotide polymorphisms with tenofovir exposure in a diverse prospective cohort of women living with HIV.Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics.Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.Precision medicine for HIV: where are we?Antimicrobial Agents

P2860

Q34534986-B27D4A04-8F55-40BE-9869-B22BC5552163 Q35230243-9AE2F968-753A-4D1E-A1DE-90E85DFA060F Q36320379-5495E255-A1A3-40DF-B993-F4258D424509 Q40219167-4E21F9EE-55AA-4005-9445-5C58A4D3D282 Q41048998-53B07D85-53C3-4E5B-BFE3-C56030436E1A Q42215539-6DC12CCC-1445-457E-A538-647D176A896F Q47569821-99CBD871-F642-49E1-8452-B68AC822E701 Q57549163-FFF71F57-C5F8-46D6-B240-306E68636FEA

P2860

Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.

http://www.wikidata.org/entity/Q37866298

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 April 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Antiretroviral drug toxicity i ...... profile and pharmacogenetics.

@en

Antiretroviral drug toxicity i ...... profile and pharmacogenetics.

@nl

type

label

Antiretroviral drug toxicity i ...... profile and pharmacogenetics.

@en

Antiretroviral drug toxicity i ...... profile and pharmacogenetics.

@nl

prefLabel

Antiretroviral drug toxicity i ...... profile and pharmacogenetics.

@en

Antiretroviral drug toxicity i ...... profile and pharmacogenetics.

@nl

P1433

Q37866298-88E7F2F2-C3C0-4666-A0A7-1F0748F65D23

P1476

Q37866298-1D708235-B844-4D39-AF84-A4DADF73FA0E

P2093

Q37866298-B0A2E672-5F05-444A-B99D-A0B182768764

Q37866298-CBACD4DC-A0FD-41F0-8415-B90A5A85800D

P2860

Q37866298-0034D097-726B-49BF-9704-96D425BA7082

Q37866298-0538AD4A-ACEB-4C63-8F47-38AAEF77BD1C

Q37866298-0649AE08-21A6-4C1D-B52E-25D942D23167

Q37866298-06C4B8EC-137E-4C83-8B35-4DF099A5CAF1

Q37866298-08A06943-E3B5-43BE-809A-58209F08FAC0

Q37866298-0A01F678-3DF7-4B2E-8122-6C4A3C26BC88

Q37866298-0BDB3108-ABCE-4ABB-B0B2-343D7642C65E

Q37866298-0DF85586-BA67-4984-A103-8753910BE1FA

Q37866298-12D9FBFF-8D36-49AB-96C5-8A04B56BFA1C

Q37866298-15EFDC06-0ABE-4A65-AC0C-FB3D9E1CA9C3

P304

Q37866298-FFC748F6-F1B2-4B7D-BC80-3019CBD37C01

P31

Q37866298-68B711BD-8F60-448F-A1CD-C0F54334926B

P356

Q37866298-D7482809-D589-4C6B-9A15-CE4D737CDE65

P407

Q37866298-23EC91BB-CC0E-4299-A2B8-E287FF085F70

P433

Q37866298-D4B7FBCA-F916-4D82-B072-C6E316A1A078

P478

Q37866298-BBCFED53-F570-4140-B8C1-D82509207F66

P50

Q37866298-2F40653A-FE85-4452-A7B2-439D0ED51FE5

Q37866298-9AA572A8-D41E-4344-B841-FA89C0E74113

Q37866298-DBDB61E6-F974-4913-90E9-12DF2B13304E

P577

Q37866298-A31EECCF-6CB8-4FD4-924D-0B5CB5AADCDB

P698

Q37866298-A7115445-9364-43DF-B9C3-96D8EDCB82FA

P921

Q37866298-AEF4B4A8-C69B-43A7-BA0F-F30E57FB9986

P356

17425255.2011.562891

P1433

Expert Opinion on Drug Metabolism & Toxicology

P1476

Antiretroviral drug toxicity i ...... profile and pharmacogenetics.

@en

P2093

Amalio Telenti

http://www.w3.org/2001/XMLSchema#string

Mona Arab-Alameddine

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study

Raltegravir: the first HIV type 1 integrase inhibitor

Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1

Metabolic activation of nevirapine in human liver microsomes: dehydrogenation and inactivation of cytochrome P450 3A4.

CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Quantifying the metabolic activation of nevirapine in patients by integrated applications of NMR and mass spectrometries

Efavirenz in the therapy of HIV infection.

Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation

P304

609-622

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425255.2011.562891

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Laurent Arthur Decosterd

P577

2011-04-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21500966

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug